Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide

European Heart Journal

14 December 2024

Organised by:

Read full article

Contributors

Subodh Verma

Subodh Verma

Author

St. Michael's Hospital Toronto , Canada

Francesco Cosentino

Francesco Cosentino

Author

Karolinska University Hospital Stockholm , Sweden

Mikhail N Kosiborod

Mikhail N Kosiborod

Author

You may be interested in

Congress Session

A multidisciplinary approach to type 2 diabetes, obesity, and cardiovascular diseases: current evidence and a glimpse into the future

27 August 2023

Congress Presentation

Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes

1 September 2025

Webinar

GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?

24 November 2025

Congress Session

Obesity as a cardiovascular disease: integrated management

3 April 2025

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources